Investors

Investors image

News

Apr.25, 2025 Release
Shionogi Announces Further Agreement with Apnimed for Sleep Disorder Treatments - Introduction of New Assets to Joint Venture Shionogi-Apnimed Sleep Science – (SASS)
Apr.24, 2025 Release
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Apr.08, 2025 Release
ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja® / Fetroja® (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections
Apr.02, 2025 Release
Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand
Apr.01, 2025 Notice
SHIONOGI Group Code of Conduct has been issued
  • Latest IR Information

    ・Financial Results / Supplement

    　- Presentation material

    　- Transcript

    more
  • IR Library

    ・Financial Results / Supplement

    ・Presentation materials

    ・Annual Report / Integrated Report / EHS Report

    ・Corporate Governance Report

    ・Pipeline

    ・Fact Book

    more
  • Management Policy

    ・Philosophy

    ・Business Plan

    ・Corporate Governance

    ・Disclosure Policy

    ・Business Risks

    more
  • Shareholder Information

    ・Information on Shares

    ・General Meeting of Shareholders

    ・Analyst Coverage

    ・Bonds & Ratings

    more
  • Individual Investors

    ・Pharmaceutical Business

    ・Shionogi's Strength

    ・Business Strategy

    ・Business Activities, etc.

     

    more
  • Sustainability

    View the Shionogi's approach to sustainable growth

    more
  • Financial Highlights

    Financial highlights for the last five years

    more
  • IR Calendar

    The schedule and results of IR events in each fiscal year

     

    more